posted on 2025-03-14, 02:43authored bySohini Pal, Diana Huttner, Navneet C. Verma, Talya Nemirovsky, Oren Ziv, Noa Sher, Natalie Yivgi-Ohana, Amit Meller
Mitochondrial DNA
(mtDNA) quantification is crucial in
understanding
mitochondrial dysfunction, which is linked to a variety of diseases,
including cancer and neurodegenerative disorders. Traditional methods
often rely on amplification-based techniques, which can introduce
bias and lack the precision needed for clinical diagnostics. Solid-state
nanopores, an emerging biosensing platform, have the advantage of
offering single-molecule and label-free approaches by enabling the
direct counting of DNA molecules without amplification. The ion-current
signatures obtained from each DNA molecule contain rich information
on the molecules’ lengths and origin. In this study, we present
an amplification-free method for mtDNA quantification using solid-state
nanopores and machine learning. Intriguingly, we find that native
(unamplified) mtDNA translocations harbor structurally distinctive
features that can be exploited to specifically detect and quantify
mtDNA copies over the background of genomic DNA fragments. By combining
selective degradation of linear genomic DNA (gDNA) via exonuclease
V with a support vector machine (SVM)-based model, we isolate and
quantify mtDNA directly from biological samples. We validate our method
using plasmids or isolated mtDNAs by spiking in predetermined quantities.
We then quantify endogenous mtDNAs in a cancer cell line and in blood
cells and compare our results with qPCR-based quantification of the
mtDNA/nuclear DNA ratios. To elucidate the source of the ion-current
signatures from the native mtDNA molecules, we perform synchronous
electro-optical sensing of mtDNAs during passage through the nanopore
after NHS ester reaction with fluorophore compounds. Our results show
correlated electro-optical events, indicating that the mtDNA is complexed
with packaging proteins. Our assay is robust, with a high classification
accuracy and is capable of detecting mtDNA at picomolar levels, making
it suitable for low-abundance samples. This technique requires minimal
sample preparation and eliminates the need for amplification or purification
steps. The developed approach has significant potential for point-of-care
applications, offering a low-cost and scalable solution for accurate
mtDNA quantification in clinical settings.